Clinical Trial Update: A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing docetaxel plus ramucirumab versus docetaxel plus placebo in metastatic non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2016-01-20